Migraine and peptides — the indication that put a peptide-pathway class on the global formulary

Why this dossier exists

Migraine is the indication where the peptide-pathway story produced the most consequential drug-class success of the last decade, and the only indication in this corpus where targeting a peptide signalling axis has reshaped first-line preventive care across a major neurological disease. The Steiner TJ, Stovner LJ, Jensen R et al., J Headache Pain 2020, 21:137 synthesis of GBD 2019 reported migraine as the second leading cause of years lived with disability worldwide across both sexes and all ages — and the first leading cause of disability in women aged 15 to 49, displacing every other condition the GBD framework catalogues. Global prevalence sits at roughly 14–15%, with the canonical female-to-male ratio of approximately 3:1. The episodic-to-chronic spectrum runs from fewer than 15 headache days per month (episodic migraine, the modal presentation) to at least 15 headache days per month of which at least 8 are migrainous (chronic migraine, ICHD-3 1.3) — the threshold at which disability concentrates and where the modern preventive trial literature has done much of its work.

Standard of care in 2026 has three layers. Acute treatment uses the triptan class as established first-line, NSAIDs and anti-emetics as adjuncts, ergots as the older class still in use, plus the modern additions: acute oral gepants (ubrogepant, rimegepant), intranasal zavegepant, and lasmiditan — a 5-HT1F agonist without the vasoconstrictor activity that limits triptans. Preventive treatment for episodic migraine layers older orals (propranolol, topiramate, divalproex, amitriptyline) against the anti-CGRP monoclonal antibody class (erenumab, fremanezumab, galcanezumab, eptinezumab) and the preventive gepants (atogepant, rimegepant). Chronic migraine adds onabotulinumtoxinA on the PREEMPT trial body. The American Headache Society's 2024 consensus update (Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey AD, Headache 2024, 64:333–341) elevated the CGRP-targeting class to first-line status for migraine prevention without prior failure of older preventives.

This dossier walks the peptide-pathway story in migraine across three threads — the CGRP class itself (the peptide field's biggest twenty-first-century clinical success), the emerging PACAP class (a second peptide-pathway target with positive Phase 2 readouts), and the older biohacker-peptide stacks (BPC-157, Cerebrolysin) plus hormonal suppression for menstrual migraine. The honest one-line read: migraine is the peptide-pathway indication where the validated mechanism produced validated medicines, and where the practitioner-peptide overlay is correspondingly less load-bearing than in indications where no class-defining therapies exist.